 AUSTIN, Texas, Dec. 17, 2020 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ:AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of... 